Results 81 to 90 of about 6,990,613 (274)
Targeting the EpCAM‐AXL axis to overcome drug resistance in lung cancer
Lung cancer cells often evade therapy by hijacking signaling pathways. We reveal that cleaved EpCAM (sEpCAM) stabilizes the oncogenic protein AXL, driving NF‐κB and STAT3‐mediated chemoresistance. This EpCAM‐AXL axis identifies a high‐risk patient subset with poor prognosis.
Alexa Guerrero‐Alba +5 more
wiley +1 more source
Association of SII and AISI in patients with sepsis: A retrospective study
Sepsis, a life-threatening dysregulated immune response to infection, necessitates reliable biomarkers for early risk stratification and prognosis. Sepsis occurs when bacteria that cause an infection the body's overwhelming inflammatory reaction to ...
Ahmet Burak Gurpinar +2 more
doaj +1 more source
LVRF (lymphatic and vascular resistance factor) is a VEGFA splice variant upregulated in response to anti‐angiogenic therapy that fosters tumor adaptation through enhanced vascularization, lymphangiogenesis, and metastatic dissemination. Targeting LVRF with fully human neutralizing antibodies disrupts these processes and limits resistant tumor growth ...
Marion David +12 more
wiley +1 more source
Primary Care Approach to the Use of Inflammatory Indices in Hypertension: A Review [PDF]
Hypertension is increasingly recognized as a chronic low-grade inflammatory condition rather than solely a hemodynamic disorder. Hematologic indices such as neutrophil-to-lymphocyte ratio, plateletto-lymphocyte ratio, systemic immune-inflammation index ...
Seda Akyar, Hamdi Nezih Dağdeviren
doaj +1 more source
Reprogramming tumor cells with LCOR mRNA nanotherapy to enhance immunotherapy
LCOR (Ligand‐dependent corepressor) mRNA encapsulated in polymeric nanoparticles restores LCOR activity in tumor cells, constraining aggressive tumor cell states and increasing tumor immunogenicity. This reprogramming makes tumor cells more vulnerable to T‐cell attack and enhances their response to immune‐checkpoint immunotherapy.
Gabriel Serra‐Mir +9 more
wiley +1 more source
Systemic Immune-Inflammatory Index and Other Inflammatory Marker Variations in Oral Squamous Cell Carcinoma Management. [PDF]
Background and Objectives: With the greatest rate of morbidity and death, OSCC is one of the world’s most critical public health problems. Being a complex pathology, the management process that includes diagnostic, surgical, and adjuvant treatments must as well take into account the involvement of the immune system.
Nicoară A +6 more
europepmc +4 more sources
The impact of leukocyte‐associated RNA retention on platelet RNA‐based cancer detection
Platelets carry RNA signals that may help detect cancer, but platelet samples can also retain RNA from white blood cells. We found that this retained white blood cell signal did not significantly affect machine learning cancer classification, suggesting that the cancer‐related RNA signal in platelets is largely independent of leukocyte‐associated RNA ...
Michał Sieczczyński +12 more
wiley +1 more source
BackgroundLatent tuberculosis infection affects about one-quarter of the global population and can progress to active tuberculosis. Hematological inflammatory markers, such as the systemic immune-inflammation index, neutrophil-to-lymphocyte ratio ...
Yang Liu +6 more
doaj +1 more source
Systemic Immune-Inflammation Index and Systemic Inflammation Response Index Predict the Response to Radioiodine Therapy for Differentiated Thyroid Cancer [PDF]
Yan Wang,1,2 Junshun Chang,1 Ben Hu,3 Suyun Yang1 1Department of Nuclear Medicine, First Hospital of Shanxi Medical University, Taiyuan, Shanxi, 030001, People’s Republic of China; 2Academy of Medical Sciences, Shanxi Medical University, Taiyuan, Shanxi,
Wang Y, Chang J, Hu B, Yang S
core
UiO‐66(Zr) metal–organic frameworks are chemically stable, biocompatible, and highly tunable nanomaterials. Their modular structure enables controlled drug delivery, multimodal bioimaging, and light‐activated photodynamic therapy, supporting integrated diagnostic and therapeutic (theranostic) applications in cancer and biomedical research.
Veronika Huntošová +2 more
wiley +1 more source

